Skip to main content

Clifford Chance

Clifford Chance

News and awards

Clifford Chance advises Neusoft Xikang on Hong Kong IPO and Listing

  • en
  • zh
  • Language options

28 September 2023

Clifford Chance advises Neusoft Xikang on Hong Kong IPO and Listing

Global law firm Clifford Chance has acted as the international counsel to Neusoft Xikang Holding Inc. ("Neusoft Xikang") for its initial public offering and listing on the mainboard of the Hong Kong Stock Exchange.

The deal was led by China Co-Managing Partner Tim Wang and partners Fang Liu and Christine Xu with support from counsel Claire Cao, senior associates Emma Bao and Qingqing Bu, associates Yuan Cao, Yuer Shao, Xiao Yu and Jason Ng and trainee Xiao Tang.

Tim said, "We're honoured to assist Neusoft Xikang on its successful listing, which demonstrates our expertise advising the healthcare sector on IPOs and extensive experience in the Hong Kong equity capital market."

As one of the pioneers in China's digital healthcare market, Neusoft Xikang developed China's first city-specific hospital network and nurtured a hospital network on a cloud-based system that connects local governments, medical institutions, patients and insurers to enable equal access to medical resources and a more effective and efficient delivery of health care services.

Clifford Chance regularly advises on many of Hong Kong’s most significant healthcare IPOs, including Adicon, Sipai Health Technology, Dingdang Pharma, Medlive Technology and Ping An Doctor.



中国区联席管理合伙人王彦峰、合伙人方刘和许文嘉共同牵头本交易,团队成员包括曹阳 (外国法律顾问律师)、包宸、卜青青、曹嫄、邵钰儿、俞笑、吴子轩和唐潇。